Celldex Therapeutics (CLDX) Current Assets (2010 - 2026)

Celldex Therapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $459.2 million for Q1 2026.

• In Q1 2026, Current Assets fell 33.81% year-over-year to $459.2 million; the TTM figure through Mar 2026 stood at $459.2 million (down 33.81% YoY), while the FY2025 annual figure was $534.7 million, down 28.44% from the prior year.
• Current Assets was $459.2 million for Q1 2026 at Celldex Therapeutics, down from $534.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $835.3 million in Q1 2024 to a low of $245.9 million in Q3 2023.
• Historically, Current Assets has averaged $515.1 million across 5 years, with a median of $459.2 million in 2026.
• The sharpest annual moves came in 2024 and 2026: Current Assets jumped 216.69% in 2024, then tumbled 33.81% in 2026.
• A 5-year view of Current Assets shows it stood at $317.7 million in 2022, then jumped by 35.88% to $431.7 million in 2023, then soared by 73.08% to $747.2 million in 2024, then dropped by 28.44% to $534.7 million in 2025, then retreated by 14.11% to $459.2 million in 2026.
• The last three Current Assets figures came in at $459.2 million (Q1 2026), $534.7 million (Q4 2025), and $604.3 million (Q3 2025), per Business Quant data.